Inish O’Doherty, PhD
Inish O’Doherty, PhD is Executive Director of C-Path’s Type 1 Diabetes (T1D) and Transplant Therapeutic Consortium (TTC). His work focuses on the collaborative selection and development of prognostic biomarkers that can be qualified as Drug Development Tools (DDT) and Novel Methodologies with the FDA and EMA, respectively. Prior to C-Path, Dr. O’Doherty implemented chemical biology target validation methodologies in the drug discovery and development process at Pfizer Inc. During his tenure at Pfizer, Dr. O’Doherty was scientific lead for an academic collaboration with the University of California San Francisco to advance the understanding of quantitative in-cell target engagement assays in complex cellular environments. Dr. O’Doherty received his PhD from Cornell University, Ithaca, as part of the Tri-institutional Training Program in Chemical Biology (TPCB) which encompasses Weill Cornell Medical College, The Rockefeller University, and Memorial Sloan-Kettering Cancer Center. He worked on a variety of interdisciplinary projects, focusing on the design and application of chemical probes for the deconvolution of biological signaling pathways, with collaborators from several institutions, resulting in multiple publications.